Akademik Veri Yönetim Sistemi
1st International Basic Oncology Congress, 2 - 04 Haziran 2022, cilt.5, ss.31
Next-generation sequencing (NGS)-based approaches facilitated
the identification of genomic and transcriptomic alterations associated
with
the development of B-cell lymphomas. Identification of these aberrancies
during diagnosis may be helpful in choosing the most appropriate
targeted
therapy. Follicular lymphoma and Burkitt lymphoma are B-cell non-Hodgkin
lymphomas with the potential to benefit from molecular targeted
therapy. Targeted sequencing or miRNA-Seq were performed
on FFPE tumor tissues of FL and pediatric BL (pBL) cases, respectively,
using
the HiSeq system. Cancer- associated somatic mutations were identified
in FL tumor tissue DNA samples through a computational bioinformatics
pipeline.
miRNAs overexpressed in pBL cases compared with the tonsil centroblasts
of non-cancer control cases were identified through differential
expression
analyses. Sanger sequencing or qRT-PCR were used to cross-validate
targeted NGS and miRNA-Seq results, respectively. The literature search
was
performed to evaluate the therapeutic potential of these somatic
mutations and upregulated miRNAs. Targeted sequencing of FL tumor tissues revealed activating
mutations in genes of biological processes or oncogenic signaling
pathways. Several
miRNAs were identified to be significantly overexpressed in pBL cases.
The literature search revealed that targeted therapeutic approaches may
be
available for the FL or pBL patients with the identified mutations or
upregulated miRNAs in tumor tissues. Targeted NGS may be applied during diagnosis to choose
appropriate therapy for FL patients. Upregulated miRNAs provide unique
opportunities for personalized targeted therapy of pBL patients.